| Status: Superseded | ||
AWMSG advice superseded by NICE guidance issued March 2021. Refer to ID1463: Anakinra for treating active Stills disease for full guidance on NICE recommendations , including any restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | anakinra (Kineret®) 3734 | |
| Formulation | 100 mg/0.67 ml solution for injection | |
| Reference number | 3734 | |
| Indication | For the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease, with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs or glucocorticoids. |
|
| Company | Swedish Orphan Biovitrum Ltd | |
| BNF chapter | Musculoskeletal & joint diseases | |
| Assessment type | Non-submission | |
| Status | Superseded | |
| Date of issue | 25/07/2018 | |
| NICE guidance | ||